



an Open Access Journal by MDPI

Biochemical and Cellular Mechanisms Regulating ER-to-Golgi Vesicular Trafficking in Health and Disease

Guest Editors:

Dr. Paolo Remondelli

Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Via Salvador Allende, 84081 Baronissi, Italy

Dr. Ornella Moltedo

Department of Pharmacy, University of Salerno, Via Giovanni Paolo II, 84084 Fisciano, Italy

Dr. Giuseppina Amodio

Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, 84081 Baronissi, Italy

Deadline for manuscript submissions:

closed (30 April 2023)

Message from the Guest Editors

Secretory proteins and membranes exit the ER into ER-derived carriers and are transported to the Golgi before being sorted and delivered to their final destinations. This task is fundamental for the maintenance and function of secretory pathway compartments as well as for extracellular environment roles. The Unfolded Protein Response pathways, which preside over the control of proteostasis within the secretory pathway, the assembly of the multiprotein complex COPII at the ER membranes, and the ER-phagy are principal actors in ER-to-Golgi trafficking control. In this Special Issue, we welcome scientific contributions that describe novel cellular mechanisms and their interconnections implicated in ER-to-Golgi trafficking control and that discuss how defects of the molecular machinery that control ER-export result in diverse human diseases. We also welcome scientific reports that show and/or discuss possible therapeutic approaches that may be used in the treatment of ER-to Golgi trafficking-based disorders.



mdpi.com/si/102805

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)